Psychedelic Research in
Taiwan
Blossom currently tracks 8 psychedelic clinical trials connected to Taiwan. The country page also links to 1 stakeholder, giving the page ecosystem context beyond registered studies.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Taiwan.
- 1
Blossom tracks 8 psychedelic clinical trials connected to Taiwan, with none currently marked active.
- 2
Visible trial compounds include Esketamine and Ketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 1 stakeholder in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research Snapshot
Blossom currently tracks 8 psychedelic clinical trials connected to Taiwan.
- Active trials
- 0
- Total trials
- 8
- Stakeholders
- 1
- Events
- 0
None marked active
Country-linked records
Linked organisations
No linked events
Top Compounds
- Esketamine(5)
- Ketamine(3)
Top Study Topics
- Treatment-Resistant Depression (TRD)(6)
- Major Depressive Disorder (MDD)(2)
Medical Access Snapshot
Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non-medical possession and diversion are criminalized; dedicated esketamine...
Regulatory Status
The linked medical access and reimbursement guide summarises Taiwan as "Medical Only (Private)". Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside approved clinical research and are treated as illicit. Ketamine is an accepted medical anesthetic and is used clinically (and appears in addiction / forensic policing statistics), but non-medical possession and diversion are criminalized; dedicated esketamine (Spravato®) regulatory status in Taiwan is not documented in public TFDA approvals as of Feb 20, 2026.
Country Details
- Region
- Asia
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Psychedelic and entheogenic compounds in Taiwan are, as a rule, scheduled and tightly controlled under national narcotics/controlled-drugs legislation; most classical psychedelics (psilocybin, MDMA, DMT family, mescaline, ibogaine, 2C-X, ayahuasca preparations) have no authorized medical use outside...
Open access guide →Psychedelic Stakeholders in Taiwan
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Taiwan.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Taiwan.